APA
Washburn W. N., Harper T. W., Wu G., Godfrey J. D., McCann P., Girotra R., Shao C., Zhang H., Gavai A., Mikkilineni A., Dejneka T., Ahmed S., Caringal Y., Hangeland J., Zhang M., Cheng P. T. W., Russell A. D., Skwish S., Slusarchyk D. A., Allen G. T., Frohlich B. H., Abboa-Offei B. E., Cap M., Waldron T. L., George R. J., Tesfamariam B., Dickinson K. E., Seymour A. A. & Sher P. M. (20071001). Arylpropanolamines: selective beta3 agonists arising from strategies to mitigate phase I metabolic transformations. : Bioorganic & medicinal chemistry letters.
Chicago
Washburn W N, Harper T W, Wu G, Godfrey J D, McCann P, Girotra R, Shao C, Zhang H, Gavai A, Mikkilineni A, Dejneka T, Ahmed S, Caringal Y, Hangeland J, Zhang M, Cheng P T W, Russell A D, Skwish S, Slusarchyk D A, Allen G T, Frohlich B H, Abboa-Offei B E, Cap M, Waldron T L, George R J, Tesfamariam B, Dickinson K E, Seymour A A and Sher P M. 20071001. Arylpropanolamines: selective beta3 agonists arising from strategies to mitigate phase I metabolic transformations. : Bioorganic & medicinal chemistry letters.
Harvard
Washburn W. N., Harper T. W., Wu G., Godfrey J. D., McCann P., Girotra R., Shao C., Zhang H., Gavai A., Mikkilineni A., Dejneka T., Ahmed S., Caringal Y., Hangeland J., Zhang M., Cheng P. T. W., Russell A. D., Skwish S., Slusarchyk D. A., Allen G. T., Frohlich B. H., Abboa-Offei B. E., Cap M., Waldron T. L., George R. J., Tesfamariam B., Dickinson K. E., Seymour A. A. and Sher P. M. (20071001). Arylpropanolamines: selective beta3 agonists arising from strategies to mitigate phase I metabolic transformations. : Bioorganic & medicinal chemistry letters.
MLA
Washburn W N, Harper T W, Wu G, Godfrey J D, McCann P, Girotra R, Shao C, Zhang H, Gavai A, Mikkilineni A, Dejneka T, Ahmed S, Caringal Y, Hangeland J, Zhang M, Cheng P T W, Russell A D, Skwish S, Slusarchyk D A, Allen G T, Frohlich B H, Abboa-Offei B E, Cap M, Waldron T L, George R J, Tesfamariam B, Dickinson K E, Seymour A A and Sher P M. Arylpropanolamines: selective beta3 agonists arising from strategies to mitigate phase I metabolic transformations. : Bioorganic & medicinal chemistry letters. 20071001.